During the past decade, Medisch Centrum Alkmaar conducted 59 clinical trials. In the 10-year time frame, 59 clinical trials started and 18 clinical trials were completed, i.e. on average, 30.5% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 5 clinical trials were completed. i.e. 18.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Medisch Centrum Alkmaar" #1 sponsor was "The Netherlands Cancer Institute" with 8 trials, followed by "Hoffmann-La Roche" with 7 trials sponsored, "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 5 trials sponsored, "Boehringer Ingelheim" with 4 trials sponsored and "Boston Scientific Corporation" with 4 trials sponsored. Other sponsors include 82 different institutions and companies that sponsored additional 63 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Medisch Centrum Alkmaar" #1 collaborator was "ZonMw: The Netherlands Organisation for Health Research and Development" with 6 trials as a collaborator, "Borstkanker Onderzoek Groep" with 5 trials as a collaborator, "Noordwest Ziekenhuisgroep" with 5 trials as a collaborator, "Roche Pharma AG" with 5 trials as a collaborator and "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 3 trials as a collaborator. Other collaborators include 130 different institutions and companies that were collaborators in the rest 123 trials.

According to Clinical.Site data, the most researched conditions in "Medisch Centrum Alkmaar" are "Breast Cancer" (10 trials), "Coronary Artery Disease" (6 trials), "Heart Failure" (6 trials), "Atrial Fibrillation" (5 trials) and "Colorectal Cancer" (4 trials). Many other conditions were trialed in "Medisch Centrum Alkmaar" in a lesser frequency.

Most popular intervention types in "Medisch Centrum Alkmaar" are "Drug" (63 trials), "Other" (17 trials), "Device" (16 trials), "Procedure" (9 trials) and "Biological" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "Bevacizumab" (4 trials), "Paclitaxel" (4 trials), "Rituximab" (4 trials) and "prednisone" (4 trials). Other intervention names were less common.

The vast majority of trials in "Medisch Centrum Alkmaar" are 106 trials for "All" genders, 6 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Medisch Centrum Alkmaar". undefined are not yet recruiting, 20 are recruiting, 20 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 54 completed trials in Medisch Centrum Alkmaar, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Medisch Centrum Alkmaar, 2 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 56 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 19 trials that are defined as “Not Applicable".